Materias dentro de su búsqueda.
Mostrando 3,461 - 3,480 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.67s Limitar resultados
  1. 3461
    “…While in breast cancer HER2 has already been successfully used as a treatment target, there are only limited data evaluating the effects of inhibiting HER2 tyrosine kinases in patients with pancreatic cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
  2. 3462
    “…BACKGROUND: HER-2 gene testing has become an integral part of breast cancer patient diagnosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma
  3. 3463
    “…ErbB2/HER2/Neu-overexpressing breast cancers are characterized by poor survival due to high proliferation and metastasis rates and identifying downstream targets of ErbB2 should facilitate developing novel therapies for this disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
  4. 3464
    “…Significantly, the toxic small drug diffuses through the cell membrane of HER2/neu expressing cells as well as cells that lack the expression of HER2/neu, causing a bystander effect. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT
  5. 3465
    “…Trastuzumab is a humanized monoclonal antibody, which binds to the extracellular segment of the HER2/neu receptor. Nine months following the therapy her vision was stable, whilst one focus of the tumour in the affected eye, had regressed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report
  6. 3466
    “…The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression
  7. 3467
    “…Overexpression of HER-2 receptor is associated with poor prognosis and aggressive forms of breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells
  8. 3468
    “…In a previous study, we demonstrated that anti-HER-2 engineering antibody ChA21 was able to bind to subdomain I of HER-2 extracellular domain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells
  9. 3469
    “…This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients with HER2-negative ABC that recurred after anthracycline and taxane therapy were randomized (1:1) to sunitinib 37.5 mg/day or capecitabine 1,250 mg/m(2) (1,000 mg/m(2) in patients >65 years) BID on days 1–14 q3w. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
  10. 3470
    “…BACKGROUND: Esophageal adenocarcinoma (EAC) is a highly aggressive disease with poor prognosis, which frequently exhibits HER-2 gene amplification. Trastuzumab, the humanized antibody against HER-2, has potent growth inhibitory effects on HER-2 overexpressing cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
  11. 3471
    “…Here we show that HSF1 is required for cell transformation and tumorigenesis induced by HER2 oncogene responsible for aggressive breast tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Heat shock transcription factor HSF1 plays a critical role in HER2-induced cellular transformation and tumorigenesis
  12. 3472
    “…BACKGROUND: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
  13. 3473
    “…METHODS: In all, 99 patients with an HER-2-amplified breast tumour treated with trastuzumab-based neoadjuvant therapy were included. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
  14. 3474
    “…BACKGROUND: The human epidermal growth factor receptor 2 (HER2) and p53 pathways may be involved in chemotherapy sensitivity and/or resistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
  15. 3475
    “…INTRODUCTION: Many laboratories are currently evaluating the usefulness of determination of HER2, p53, and Ki67 proliferation indices using immunohistochemical techniques in cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
  16. 3476
    “…Overexpression of Her2/ErbB2/Neu in cancer is often correlated with recurrent distant metastasis, although the mechanism still remains largely elusive. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Engagement of Overexpressed Her2 with GEP100 Induces Autonomous Invasive Activities and Provides a Biomarker for Metastases of Lung Adenocarcinoma
  17. 3477
    “…BACKGROUND: HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
  18. 3478
    “…INTRODUCTION: Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
  19. 3479
    por Shiroiwa, T, Fukuda, T, Shimozuma, K
    Publicado 2011
    “…BACKGROUND: We performed a cost-effectiveness analysis of trastuzumab plus chemotherapy for human epidermal growth factor type-2 (HER2)-positive advanced gastric cancer (GC) based on data obtained from the Trastuzumab for Gastric Cancer (ToGA) trial from a Japanese perspective. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
  20. 3480
    “…The expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers
Herramientas de búsqueda: RSS